{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:22:48Z","timestamp":1772137368115,"version":"3.50.1"},"reference-count":48,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.3892\/or.2015.4509","type":"journal-article","created":{"date-parts":[[2015,12,22]],"date-time":"2015-12-22T13:41:39Z","timestamp":1450791699000},"page":"1732-1740","source":"Crossref","is-referenced-by-count":43,"title":["Consecutive salinomycin treatment reduces doxorubicin resistance of breast tumor cells by diminishing drug efflux pump expression and activity"],"prefix":"10.3892","volume":"35","author":[{"given":"ADAM","family":"HERMAWAN","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ERNST","family":"WAGNER","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ANDREAS","family":"ROIDL","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2015,12,22]]},"reference":[{"key":"key20180107210606_b1-or-35-03-1732","volume-title":"World Cancer Report 2014","author":"Stewart","year":"2015"},{"key":"key20180107210606_b2-or-35-03-1732","first-page":"155","article-title":"Membrane rafts as a novel target in cancer therapy","volume":"1845","author":"Hryniewicz-Jankowska","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"key20180107210606_b3-or-35-03-1732","first-page":"1197","article-title":"Signalling pathways involved in endocrine resistance in breast cancer and associations with epithelial to mesenchymal transition (Review)","volume":"38","author":"Al Saleh","year":"2011","journal-title":"Int J Oncol"},{"key":"key20180107210606_b4-or-35-03-1732","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.suronc.2009.01.004","article-title":"Breast cancer chemoresistance: Emerging importance of cancer stem cells","volume":"19","author":"Chuthapisith","year":"2010","journal-title":"Surg Oncol"},{"key":"key20180107210606_b5-or-35-03-1732","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/phar.1338","article-title":"Pertuzumab: A new targeted therapy for HER2-positive metastatic breast cancer","volume":"34","author":"Malenfant","year":"2014","journal-title":"Pharmacotherapy"},{"issue":"Suppl 3","key":"key20180107210606_b6-or-35-03-1732","doi-asserted-by":"crossref","first-page":"S100","DOI":"10.3816\/CBC.2008.s.006","article-title":"Circumventing de novo and acquired resistance to trastuzumab: New hope for the care of ErbB2-positive breast cancer","volume":"8","author":"Piccart","year":"2008","journal-title":"Clin Breast Cancer"},{"key":"key20180107210606_b7-or-35-03-1732","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2174\/156800906777723958","article-title":"Biomarkers and multiple drug resistance in breast cancer","volume":"6","author":"O'Driscoll","year":"2006","journal-title":"Curr Cancer Drug Targets"},{"key":"key20180107210606_b8-or-35-03-1732","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-0-387-74039-3_1","article-title":"Overview of resistance to systemic therapy in patients with breast cancer","volume":"608","author":"Gonzalez-Angulo","year":"2007","journal-title":"Adv Exp Med Biol"},{"key":"key20180107210606_b9-or-35-03-1732","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.cell.2009.06.034","article-title":"Identification of selective inhibitors of cancer stem cells by high-throughput screening","volume":"138","author":"Gupta","year":"2009","journal-title":"Cell"},{"key":"key20180107210606_b10-or-35-03-1732","doi-asserted-by":"crossref","first-page":"e66931","DOI":"10.1371\/journal.pone.0066931","article-title":"Inhibitory effects of salinomycin on cell survival, colony growth, migration, and invasion of human non-small cell lung cancer A549 and LNM35: Involvement of NAG-1","volume":"8","author":"Arafat","year":"2013","journal-title":"PLoS One"},{"key":"key20180107210606_b11-or-35-03-1732","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1016\/j.bbagen.2013.01.010","article-title":"Salinomycin induces apoptosis and senescence in breast cancer: Upregulation of p21, downregulation of survivin and histone H3 and H4 hyperacetylation","volume":"1830","author":"Al Dhaheri","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"key20180107210606_b12-or-35-03-1732","doi-asserted-by":"crossref","first-page":"e693","DOI":"10.1038\/cddis.2013.223","article-title":"Salinomycin induces cell death via inactivation of Stat3 and downregulation of Skp2","volume":"4","author":"Koo","year":"2013","journal-title":"Cell Death Dis"},{"key":"key20180107210606_b13-or-35-03-1732","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.4161\/auto.24632","article-title":"Salinomycin induces cell death with autophagy through activation of endoplasmic reticulum stress in human cancer cells","volume":"9","author":"Li","year":"2013","journal-title":"Autophagy"},{"key":"key20180107210606_b14-or-35-03-1732","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/bjc.2011.530","article-title":"Salinomycin inhibits prostate cancer growth and migration via induction of oxidative stress","volume":"106","author":"Ketola","year":"2012","journal-title":"Br J Cancer"},{"key":"key20180107210606_b15-or-35-03-1732","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.canlet.2014.12.037","article-title":"Salinomycin inhibits growth of pancreatic cancer and cancer cell migration by disruption of actin stress fiber integrity","volume":"358","author":"Schenk","year":"2015","journal-title":"Cancer Lett"},{"key":"key20180107210606_b16-or-35-03-1732","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1476-4598-13-16","article-title":"Salinomycin treatment reduces metastatic tumor burden by hampering cancer cell migration","volume":"13","author":"Kopp","year":"2014","journal-title":"Mol Cancer"},{"key":"key20180107210606_b17-or-35-03-1732","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.bbrc.2010.03.138","article-title":"Salinomycin overcomes ABC transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like KG-1a cells","volume":"394","author":"Fuchs","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"key20180107210606_b18-or-35-03-1732","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.bbrc.2009.10.042","article-title":"Salinomycin induces apoptosis and overcomes apoptosis resistance in human cancer cells","volume":"390","author":"Fuchs","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"key":"key20180107210606_b19-or-35-03-1732","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/j.1476-5381.2010.01089.x","article-title":"Salinomycin sensitizes cancer cells to the effects of doxorubicin and etoposide treatment by increasing DNA damage and reducing p21 protein","volume":"162","author":"Kim","year":"2011","journal-title":"Br J Pharmacol"},{"key":"key20180107210606_b20-or-35-03-1732","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1186\/1471-2407-13-490","article-title":"Salinomycin increases chemosensitivity to the effects of doxorubicin in soft tissue sarcomas","volume":"13","author":"Liffers","year":"2013","journal-title":"BMC Cancer"},{"key":"key20180107210606_b21-or-35-03-1732","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.toxlet.2013.07.022","article-title":"Salinomycin induces apoptosis in cisplatin-resistant colorectal cancer cells by accumulation of reactive oxygen species","volume":"222","author":"Zhou","year":"2013","journal-title":"Toxicol Lett"},{"key":"key20180107210606_b22-or-35-03-1732","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.3892\/or.2013.2241","article-title":"Antitumor properties of salinomycin on cisplatin-resistant human ovarian cancer cells in vitro and in vivo: Involvement of p38 MAPK activation","volume":"29","author":"Zhang","year":"2013","journal-title":"Oncol Rep"},{"key":"key20180107210606_b23-or-35-03-1732","doi-asserted-by":"crossref","first-page":"e94438","DOI":"10.1371\/journal.pone.0094438","article-title":"Salinomycin potentiates the cytotoxic effects of TRAIL on glioblastoma cell lines","volume":"9","author":"Calzolari","year":"2014","journal-title":"PLoS One"},{"key":"key20180107210606_b24-or-35-03-1732","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1002\/ijc.27595","article-title":"Combinatorial treatment of mammospheres with trastuzumab and salinomycin efficiently targets HER2-positive cancer cells and cancer stem cells","volume":"131","author":"Oak","year":"2012","journal-title":"Int J Cancer"},{"key":"key20180107210606_b25-or-35-03-1732","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.3892\/mmr.2015.3633","article-title":"Salinomycin enhances doxorubicin-induced cytotoxicity in multidrug resistant MCF-7\/MDR human breast cancer cells via decreased efflux of doxorubicin","volume":"12","author":"Kim","year":"2015","journal-title":"Mol Med Rep"},{"key":"key20180107210606_b26-or-35-03-1732","doi-asserted-by":"crossref","first-page":"e50469","DOI":"10.1371\/journal.pone.0050469","article-title":"miR-200c sensitizes breast cancer cells to doxorubicin treatment by decreasing TrkB and Bmi1 expression","volume":"7","author":"Kopp","year":"2012","journal-title":"PLoS One"},{"key":"key20180107210606_b27-or-35-03-1732","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.tranon.2014.09.002","article-title":"Sequential salinomycin treatment results in resistance formation through clonal selection of epithelial-like tumor cells","volume":"7","author":"Kopp","year":"2014","journal-title":"Transl Oncol"},{"key":"key20180107210606_b28-or-35-03-1732","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00280-010-1385-y","article-title":"Effect of MDR modulators verapamil and promethazine on gene expression levels of MDR1 and MRP1 in doxorubicin-resistant MCF-7 cells","volume":"67","author":"D\u00f6nmez","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"key20180107210606_b29-or-35-03-1732","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1476-4598-11-13","article-title":"Downregulation of HuR as a new mechanism of doxorubicin resistance in breast cancer cells","volume":"11","author":"Latorre","year":"2012","journal-title":"Mol Cancer"},{"key":"key20180107210606_b30-or-35-03-1732","doi-asserted-by":"crossref","first-page":"5822","DOI":"10.1016\/j.jprot.2012.07.047","article-title":"Proteomic analysis of proteins responsible for the development of doxorubicin resistance in human uterine cancer cells","volume":"75","author":"Lin","year":"2012","journal-title":"J Proteomics"},{"key":"key20180107210606_b31-or-35-03-1732","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12953-014-0057-y","article-title":"Comparative proteomics analysis of differential proteins in respond to doxorubicin resistance in myelogenous leukemia cell lines","volume":"13","author":"Qinghong","year":"2015","journal-title":"Proteome Sci"},{"key":"key20180107210606_b32-or-35-03-1732","doi-asserted-by":"crossref","first-page":"10350","DOI":"10.18632\/oncotarget.3585","article-title":"Salinomycin decreases doxorubicin resistance in hepatocellular carcinoma cells by inhibiting the \u03b2-catenin\/TCF complex association via FOXO3a activation","volume":"6","author":"Zhou","year":"2015","journal-title":"Oncotarget"},{"key":"key20180107210606_b33-or-35-03-1732","doi-asserted-by":"crossref","first-page":"M57","DOI":"10.1016\/S0962-8924(99)01661-X","article-title":"Genetic instability and Darwinian selection in tumours","volume":"9","author":"Cahill","year":"1999","journal-title":"Trends Cell Biol"},{"key":"key20180107210606_b34-or-35-03-1732","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jtbi.2004.07.018","article-title":"A proposal for the physiological significance of mdr1 and Bcrp1\/Abcg2 gene expression in normal tissue regeneration and after cancer therapy","volume":"232","author":"Israeli","year":"2005","journal-title":"J Theor Biol"},{"key":"key20180107210606_b35-or-35-03-1732","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1158\/1535-7163.MCT-07-0148","article-title":"Inhibition of the mitogen-activated protein kinase pathway results in the down-regulation of P-glycoprotein","volume":"6","author":"Katayama","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"key20180107210606_b36-or-35-03-1732","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/nm0901-1028","article-title":"The ABC transporter Bcrp1\/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype","volume":"7","author":"Zhou","year":"2001","journal-title":"Nat Med"},{"key":"key20180107210606_b37-or-35-03-1732","doi-asserted-by":"crossref","first-page":"7340","DOI":"10.1038\/sj.onc.1206938","article-title":"Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2)","volume":"22","author":"Doyle","year":"2003","journal-title":"Oncogene"},{"key":"key20180107210606_b38-or-35-03-1732","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/j.tiv.2010.07.020","article-title":"Reversal of P-glycoprotein-mediated multidrug resistance in vitro by milbemycin compounds in adriamycin-resistant human breast carcinoma (MCF-7\/adr) cells","volume":"24","author":"Xiang","year":"2010","journal-title":"Toxicol In Vitro"},{"key":"key20180107210606_b39-or-35-03-1732","doi-asserted-by":"crossref","first-page":"20130109","DOI":"10.1098\/rstb.2013.0109","article-title":"Ion channels and transporters in the development of drug resistance in cancer cells","volume":"369","author":"Hoffmann","year":"2014","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"key20180107210606_b40-or-35-03-1732","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1111\/j.1432-1033.1995.tb20352.x","article-title":"Potentiation of anticancer-drug cytotoxicity by multidrug-resistance chemosensitizers involves alterations in membrane fluidity leading to increased membrane permeability","volume":"228","author":"Drori","year":"1995","journal-title":"Eur J Biochem"},{"key":"key20180107210606_b41-or-35-03-1732","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/bcpt.12250","article-title":"Triggering of erythrocyte cell membrane scrambling by salinomycin","volume":"115","author":"Bissinger","year":"2014","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"key20180107210606_b42-or-35-03-1732","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1128\/AAC.9.4.655","article-title":"Salinomycin effects on mitochondrial ion translocation and respiration","volume":"9","author":"Mitani","year":"1976","journal-title":"Antimicrob Agents Chemother"},{"key":"key20180107210606_b43-or-35-03-1732","doi-asserted-by":"crossref","first-page":"14989","DOI":"10.1021\/ja075024l","article-title":"Conformation and location of membrane-bound salinomycin-sodium complex deduced from NMR in isotropic bicelles","volume":"129","author":"Matsumori","year":"2007","journal-title":"J Am Chem Soc"},{"key":"key20180107210606_b44-or-35-03-1732","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1038\/cddis.2011.46","article-title":"Salinomycin induces calpain and cytochrome c-mediated neuronal cell death","volume":"2","author":"Boehmerle","year":"2011","journal-title":"Cell Death Dis"},{"key":"key20180107210606_b45-or-35-03-1732","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/clpt.2011.14","article-title":"Multidrug efflux pumps and cancer stem cells: Insights into multidrug resistance and therapeutic development","volume":"89","author":"Moitra","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"key20180107210606_b46-or-35-03-1732","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/stem.200011","article-title":"ABC transporters as phenotypic markers and functional regulators of stem cells","volume":"20","author":"Bunting","year":"2002","journal-title":"Stem Cells"},{"key":"key20180107210606_b47-or-35-03-1732","first-page":"5002","article-title":"Reversal mechanism of multidrug resistance by verapamil: Direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562\/ADM cells","volume":"49","author":"Yusa","year":"1989","journal-title":"Cancer Res"},{"key":"key20180107210606_b48-or-35-03-1732","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1124\/pr.56.2.6","article-title":"Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity","volume":"56","author":"Minotti","year":"2004","journal-title":"Pharmacol Rev"}],"container-title":["Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/or.2015.4509\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,7]],"date-time":"2018-01-07T21:06:17Z","timestamp":1515359177000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/or.2015.4509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,22]]},"references-count":48,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2015,12,22]]},"published-print":{"date-parts":[[2016,3]]}},"alternative-id":["10.3892\/or.2015.4509"],"URL":"https:\/\/doi.org\/10.3892\/or.2015.4509","relation":{},"ISSN":["1021-335X","1791-2431"],"issn-type":[{"value":"1021-335X","type":"print"},{"value":"1791-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,22]]}}}